Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180014/S013

XPS with Steen Solution Perfusate

Xvivo Perfusion, Inc. · Decision date Nov 25, 2025

FDA DECISIONP180014/S013

What did the FDA approve?

FDA records P180014/S013 as a supplement to PMA P180014, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 25, 2025.

FDA approval order statement

Approval for material changes to the organ chamber elbow fitting and the lung cannula set luer connector
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Gastroenterology, Urology
Decision date
Nov 25, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P180014/S013
Regulatory pathway
PMA supplement
Product code
PHO
Decision code
APPR
Decision date
Nov 25, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.

Product code
PHO
FDA device class
3

For the original device and its historical approval scope, see PMA P180014. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P180014 · Original PMA

    XPS with Steen Solution Perfusate

  2. P180014/S013 received

    Application receipt date recorded by FDA.

  3. P180014/S013 · FDA decision

    Real-Time Process

  4. P180014/S014 · Related supplement

    XPS with Steen Solution Perfusate

Timeline entries are records held by MedtechLedger for P180014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180014

Product / regulatory recordCompanyPathwayDecision dateSource
Xvivo Perfusion, Inc.PMA approvalApr 26, 2019FDA
Xvivo Perfusion, Inc.PMA supplementSep 16, 2026FDA

Explore the linked device profile

Other records with product code PHO

Product / regulatory recordCompanyPathwayDecision dateSource
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA
LungFX DeviceP240033/S001
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA
LungFX DeviceP240033/S002
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA
Traferox Technologies, Inc.PMA approvalJul 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Xvivo Perfusion, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3666 S Inca St., Englewood, CO, 80110

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records